Can Fite Biopharma Ltd

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

Can-Fite Announces Scientific Breakthrough Publication Demonstrating Anti-Obesity Effect of Namodenoson

Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy